YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a…Read More
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of 96 Million ContraFect NASDAQCFRX
